Nina Shah, MD, discusses the biggest news from the FDA for multiple myeloma in the past year.
Nina Shah, MD: The biggest FDA news that we got this year was the approval of ide-cel [idecabtagene vicleucel; Abecma]. The reason it’s a big deal for us is that it now changes how we think about our lines 1, 2, 3, and 4, approaching a patient with multiple myeloma, and it allowed us to start getting our hands wet with how to use this and the logistics of that. It’s going to change how we, for example, have apheresis spots in our clinics or what kind of referral patterns we have in the community. It was nice to get that approval to start the ball rolling to hopefully bring this therapy to more patients.
FDA Approves Cilta-Cel for Relapsed/Refractory Myeloma After 1 Therapy
April 6th 2024The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of treatment, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.